Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.77 |
| ▸ | SQLE | Q14534 | 8/20 | 0.74 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Squalene SCHEMBL28621919 | 0.88 | KMT2A (0.81) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| Squalene SCHEMBL28621917 | 0.88 | KMT2A (0.81) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL8013144 | 0.88 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| Squalene SCHEMBL890053 | 0.88 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| Squalene SCHEMBL2799805 | 0.88 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL23802597 | 0.88 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| Squalene SCHEMBL8819997 | 0.88 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| Squalene SCHEMBL21823197 | 0.88 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL21639794 | 0.88 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL39067 | 0.88 | KMT2A (1.00) | KMT2ASQLEMAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110664757-B | Nanocrystalline eye drop, preparation method and application thereof | 成都瑞沐生物医药科技有限公司 | 2022-08-02 | — | — | CN | disclosed |
| US-10874740-B2 | 5-ALA derivatives and use thereof | UNIVERSITE DE GENEVE (CH) | 2020-12-29 | — | — | US | disclosed |
| EP-3297675-B1 | 5-ALA DERIVATIVES | UNIV GENEVE (CH) | 2020-07-08 | — | — | EP | disclosed |
| CN-110664757-A | Nanocrystalline eye drop, preparation method and application thereof | 成都瑞沐生物医药科技有限公司 | 2020-01-10 | — | — | CN | disclosed |
| US-20190240329-A1 | 5-ALA DERIVATIVES AND USE THEREOF | UNIVERSITE DE GENEVE (CH) | 2019-08-08 | — | — | US | disclosed |
| US-10258690-B2 | 5-ALA derivatives and use thereof | UNIVERSITE DE GENEVE (CH) | 2019-04-16 | — | — | US | disclosed |
| US-20180133320-A1 | 5-ALA DERIVATIVES AND USE THEREOF | UNIVERSITE DE GENEVE (CH) | 2018-05-17 | — | — | US | disclosed |
| EP-3297675-A1 | 5-ALA DERIVATIVES AND USE THEREOF | Université de Genève (CH) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016185368-A1 | 5-ALA DERIVATIVES AND USE THEREOF | UNIVERSITE DE GENEVE (CH) | 2016-11-24 | — | — | WO | disclosed |
| EP-3095464-A1 | 5-ALA DERIVATIVES AND USE THEREOF | UNIVERSITE DE GENEVE (CH) | 2016-11-23 | — | — | EP | disclosed |
| US-8962552-B2 | Nanoparticles of therapeutic agents having low water solubility | CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE (FR) | 2015-02-24 | — | — | US | disclosed |
| US-20110269731-A1 | NANOPARTICLES OF BETA-LACTAM DERIVATIVES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-11-03 | — | — | US | disclosed |
| US-20100305030-A1 | NANOPARTICLES OF THERAPEUTIC AGENTS HAVING LOW WATER SOLUBILITY | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-12-02 | — | — | US | disclosed |
| CN-1512890-A | HCG formulation | 开米卡公司 | 2004-07-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240329-A1 | 5-ALA DERIVATIVES AND USE THEREOF | ALAD, ANXA5, AAAS | KMT2A 2690/4885SQLE 396/4885MAPT 3634/4885 |
| US-20180133320-A1 | 5-ALA DERIVATIVES AND USE THEREOF | ALAD, ANXA5, AAAS | KMT2A 2690/4885SQLE 396/4885MAPT 3634/4885 |
| US-10874740-B2 | 5-ALA derivatives and use thereof | ALAD, ANXA5, AAAS | KMT2A 2690/4885SQLE 396/4885MAPT 3634/4885 |
| US-20110269731-A1 | NANOPARTICLES OF BETA-LACTAM DERIVATIVES | BACE1, BBOX1, PTMS | KMT2A 466/4885SQLE 1001/4885MAPT 897/4885 |
| US-20100305030-A1 | NANOPARTICLES OF THERAPEUTIC AGENTS HAVING LOW WATER SOLUBILITY | AQP1, CD44, AQP3 | KMT2A 2067/4885SQLE 10/4885MAPT 579/4885 |
| US-10258690-B2 | 5-ALA derivatives and use thereof | ALAD, ANXA5, AAAS | KMT2A 2690/4885SQLE 396/4885MAPT 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.